Clinical Response With Pembrolizumab for Cutaneous Squamous Cell Carcinoma-Reference-Cited by-同舟云学术

Clinical Response With Pembrolizumab for Cutaneous Squamous Cell Carcinoma

Published:2024-06-01 Issue:6 Volume:150 Page:524
ISSN:2168-6181
Container-title:JAMA Otolaryngology–Head & Neck Surgery
language:en
Short-container-title:JAMA Otolaryngol Head Neck Surg

Author:

Corbett Mel¹,Tohani Shivangy¹,Ramli Ruzaimi¹,O’Duffy Fergal¹²³

Affiliation:

1. University College Dublin Head and Neck Oncology Group, Dublin, Ireland

2. Department of Head and Neck Surgery, Saint Vincent’s University Hospital, Dublin, Ireland

3. Department of Head and Neck Surgery, The Mater Misericordiae University Hospital, Dublin, Ireland

Abstract

This case report describes an 89-year-old patient with prior cutaneous squamous cell carcinoma who presented with a new isolated metastasis and was subsequently treated with pembrolizumab, which produced a complete clinical response.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamaotolaryngology/articlepdf/2817535/jamaotolaryngology_corbett_2024_lo_240002_1717443203.39157.pdf

Reference6 articles.

1. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).;Cohen;J Immunother Cancer,2019

2. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by Oncology Healthcare Professionals.;Azam;Case Rep Oncol,2019

3. Abstract CT285: KEYNOTE-689: a phase 3 study of neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC).;Lee;Cancer Res,2020

4. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.;Burtness;Lancet,2019

5. Institute for Quality and Efficiency in Health Care. Pembrolizumab (Keytruda) used on its own for the treatment of advanced, incurable head and neck cancer. 2020. Accessed January 10, 2023. https://www.ncbi.nlm.nih.gov/books/NBK556940/

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutaneous Squamous Cell Carcinoma is a Different Diagnosis From Head and Neck Squamous Cell Carcinoma—Reply;JAMA Otolaryngology–Head & Neck Surgery;2024-09-01

2. Cutaneous Squamous Cell Carcinoma is a Different Diagnosis From Head and Neck Squamous Cell Carcinoma;JAMA Otolaryngology–Head & Neck Surgery;2024-09-01